Francine Blei
Pediatric Hematology-Oncology · New York, NYNPI 1982698106
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $2,675 with a category attached, or 93.5%. Every reported general payment came from a single manufacturer, Pierre Fabre Pharmaceuticals, Inc.. Reporting peaked in 2019 at $2,500 and has fallen 95.6% since, to $109 in 2024.
Across 4 payments — averaging $668.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pierre Fabre Pharmaceuticals, Inc.$3K
Across 9 payments — averaging $587,176 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5.3M
What the payments were for
- Speaking & faculty fees$2,50093%
- Food & beverage$1757%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pierre Fabre Pharmaceuticals, Inc. | 4 | $2,675 |
How this compares
$2,675 in reported general payments places this provider in the 70th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in New York
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- James FerraraNew York$118K
- John LevineNew York$98K
- Nai-Kong CheungNew York$86K
- Andrew HarrisNew York$85K
- Joseph OvedNew York$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.